Pirlindole (Pyrazidol) 25 mg – [50 tablets]

Pirlindol is an indole derivative that has elements of structural similarity with serotonin as well as with reserpine. Pirlindol has a pronounced antidepressant activity, peculiarity of its action is the presence of its thymoleptic effect with a balanced effect (activating effect in patients with apathetic, anergic depression, combined with sedative and anxiolytic action in patients with agitated states). Selectively inhibits monoamine oxidase (MAO) type A (briefly and completely reversible); blocks deamination of serotonin and noradrenaline, to a lesser extent – tyramine (which creates less preconditions for the development of tyramine (“cheese”) syndrome); partially inhibits monoamine reuptake. Activates the processes of synaptic transmission of nerve excitation in the CNS. Weakens the depressive effects of reserpine, enhances the effects of norepinephrine precursor – dioxyphenylalanine (L-dopa), stimulates adrenergic structures; potentiates the effects of serotonin precursor – 5-oxytryptophan (stimulates serotoninergic structures). Unlike tricyclic antidepressants, it has no anticholinergic effect. It also has a nootropic effect and improves cognitive functions. Pirlindole does not cumulate in the body, has no tolerance, and does not cause dependence or withdrawal syndrome.

Manic depressive psychosis, schizophrenia. Depression of various genesis, mainly with psychomotor retardation and asthenic disorders, with anxious-depressive or anxious-delirious component. Involutionary depression. Alcohol withdrawal syndrome. Alzheimer’s disease (as part of complex therapy).

Contraindications .

Hypersensitivity to the drug, acute hepatitis, diseases of the hematopoietic system, receiving monoamine oxidase inhibitors (see “Special indications”).

Administration during pregnancy and lactation

Not recommended. There are no adequate and well-controlled clinical studies on the use of the drug during pregnancy and breastfeeding. It is known that the use of tricyclic antidepressants and similar drugs in the third trimester of pregnancy may cause tachycardia, increased excitability, muscle spasms in the newborn. The drug administration is allowed only if the benefit to the mother exceeds the possible risk to the fetus.